Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New directions for erectile dysfunction therapies.

K E Andersson1, P Hedlund

  • 1Department of Clinical Pharmacology, Lund University Hospital, S-22185, Lund, Sweden. Karl-Erik.Andersson@klinfarm.lu.se

International Journal of Impotence Research
|February 19, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Calcium antagonists. Great tissue selectivity is the basis of their therapeutic use].

Lakartidningen·1997
Same author

Neurotransmitter release evoked by alpha-latrotoxin in the smooth muscle of the female pig urethra.

Naunyn-Schmiedeberg's archives of pharmacology·1997
Same author

NANC transmitters in the female pig urethra--localization and modulation of release via alpha 2-adrenoceptors and potassium channels.

British journal of pharmacology·1997
Same author

Morphological relations between haem oxygenases, NO-synthase and VIP in the canine and feline gastrointestinal tracts.

Journal of the autonomic nervous system·1997
Same author

Characterization of angiotensin II formation in human isolated bladder by selective inhibitors of ACE and human chymase: a functional and biochemical study.

British journal of pharmacology·1997
Same author

Stimulation of bladder activity by volume, L-dopa and capsaicin in normal conscious rats--effects of spinal alpha 1-adrenoceptor blockade.

Naunyn-Schmiedeberg's archives of pharmacology·1997

Future erectile dysfunction therapies focus on improving current treatments like PDE inhibitors and exploring new drug combinations. Research also targets novel central and peripheral pathways, gene therapy, and prevention strategies for enhanced erectile function.

Area of Science:

  • Urology
  • Pharmacology
  • Reproductive Medicine

Background:

  • Erectile dysfunction (ED) research is rapidly advancing.
  • Current therapies include phosphodiesterase (PDE) inhibitors and apomorphine.

Purpose of the Study:

  • To outline future directions for erectile dysfunction (ED) therapies.
  • To identify emerging treatment principles and research targets.

Main Methods:

  • Review of current and emerging therapeutic principles for ED.
  • Exploration of novel drug targets and treatment modalities.

Main Results:

  • Future therapies may involve improved PDE inhibitors, novel dopamine receptor agonists, and combination therapies.
  • New targets include central nervous system pathways (melanocortin receptors) and peripheral targets (Rho-kinase).

Related Experiment Videos

  • Gene therapy and prevention strategies are also promising avenues.

    • Conclusions:

    • Future ED treatment will likely involve a multi-faceted approach.
    • Advancements in drug development, gene therapy, and preventative measures are expected.
    • Personalized treatment strategies will be crucial for managing ED.